Company Description
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer.
The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform.
It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | William Quinn |
Contact Details
Address: 900 Chesapeake Drive Redwood City, California 94063 United States | |
| Phone | 650 665 9295 |
| Website | boltbio.com |
Stock Details
| Ticker Symbol | BOLT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 1641281 |
| CUSIP Number | 097702203 |
| ISIN Number | US0977022039 |
| Employer ID | 47-2804636 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William P. Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary and Director |
| Grant Yonehiro C.F.A., M.B.A. | Chief Operating Officer and Chief Business Officer |
| Dr. Michael N. Alonso Ph.D. | Senior Vice President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K | Current Report |
| Oct 6, 2026 | 8-K | Current Report |
| Aug 13, 2026 | SCHEDULE 13G | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |